Corrigendum: Randomized, crossover questionnaire survey of acceptabilities of controlled-release mesalazine tablets and granules in ulcerative colitis patients
Article information
Intest Res. 2020;18(3):343-344
Keiji Yagisawa1,
Taku Kobayashi2,
Ryo Ozaki2,
Shinji Okabayashi2,
Takahiko Toyonaga2,
Miki Miura3,
Mari Hayashida3,
Eiko Saito2,
Masaru Nakano2,
Hajime Matsubara1,
Tadakazu Hisamatsu3,
Toshifumi Hibi2
1Department of Pharmacy and Kitasato University Kitasato Institute Hospital, Tokyo, Japan
2Center for Advanced IBD Research and Treatment, Kitasato University Kitasato Institute Hospital, Tokyo, Japan
3The Third Department of Internal Medicine, Kyorin University School of Medicine, Tokyo, Japan
https://doi.org/10.5217/ir.2018.00078
Intest Res 2019;17(1):87-93
In the version of this article initially published, Figure 2 contains errors in the content of the questionnaire.
On page 89, the figure should be corrected as following.
From:
(A) Questionnaire 1: acceptability of tablets. (B) Questionnaire 2: acceptability of granules. (C) Questionnaire 3: comparison of tablets and granules. All the original questionnaires were written in Japanese. CR, controlled-release.
To:
(A) Questionnaire 1: acceptability of tablets. (B) Questionnaire 2: acceptability of granules. (C) Questionnaire 3: comparison of tablets and granules. All the original questionnaires were written in Japanese. CR, controlled-release.
Article information Continued
© Copyright 2020. Korean Association for the Study of Intestinal Diseases. All rights reserved.
Fig. 2.
(A) Questionnaire 1: acceptability of tablets. (B) Questionnaire 2: acceptability of granules. (C) Questionnaire 3: comparison of tablets and granules. All the original questionnaires were written in Japanese. CR, controlled-release.
Fig. 2.
(A) Questionnaire 1: acceptability of tablets. (B) Questionnaire 2: acceptability of granules. (C) Questionnaire 3: comparison of tablets and granules. All the original questionnaires were written in Japanese. CR, controlled-release.